ATAI Life Sciences Analyst Ratings
Maxim Group Maintains ATAI Life Sciences(ATAI.US) With Buy Rating, Maintains Target Price $6
CCORF Maintains ATAI Life Sciences(ATAI.US) With Buy Rating, Maintains Target Price $11
Buy Rating Affirmed for ATAI Life Sciences With Promising Clinical Outlook and Strategic Pipeline Reprioritization
TD Cowen Maintains ATAI Life Sciences(ATAI.US) With Buy Rating
TD Cowen Maintains ATAI Life Sciences(ATAI.US) With Buy Rating
Strong Buy Rating for ATAI Life Sciences on Promising Clinical Data and Solid Financials
ATAI Life Sciences Analyst Ratings
H.C. Wainwright Maintains ATAI Life Sciences(ATAI.US) With Buy Rating, Maintains Target Price $15
ATAI Life Sciences Analyst Ratings
ATAI Life Sciences Analyst Ratings
Buy Rating Affirmed for ATAI Life Sciences Amid Promising TRD Treatment Developments and Strategic Growth Potential
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Celcuity (CELC) and ATAI Life Sciences (ATAI)
ATAI Life Sciences Analyst Ratings
Atai Life Sciences Upgraded at Maxim on Beckley Investment
ATAI Life Sciences Analyst Ratings
ATAI Life Sciences Analyst Ratings
Buy Rating Affirmed for ATAI Life Sciences on Promising TRD Treatment Trial Outcomes and Strong Valuation Prospects
Analysts Offer Insights on Healthcare Companies: ATAI Life Sciences (ATAI), Halozyme (HALO) and Natera (NTRA)
HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $20 Price Target
No Data
No Data